相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody Against Integrin αvβ3, ± Dacarbazine in Patients With Stage IV Metastatic Melanoma
Peter Hersey et al.
CANCER (2010)
Integrin Alpha 6 Regulates Glioblastoma Stem Cells
Justin D. Lathia et al.
CELL STEM CELL (2010)
Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2010)
Targeting integrins in malignant glioma
Ghazaleh Tabatabai et al.
TARGETED ONCOLOGY (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Integrins in cancer: biological implications and therapeutic opportunities
Jay S. Desgrosellier et al.
NATURE REVIEWS CANCER (2010)
Mammary Epithelial-Specific Ablation of the Focal Adhesion Kinase Suppresses Mammary Tumorigenesis by Affecting Mammary Cancer Stem/Progenitor Cells
Ming Luo et al.
CANCER RESEARCH (2009)
Specific Cross-talk between Epidermal Growth Factor Receptor and Integrin αvβ5 Promotes Carcinoma Cell Invasion and Metastasis
Jill M. Ricono et al.
CANCER RESEARCH (2009)
αvβ3/αvβ5 Integrins-FAK-RhoB: A Novel Pathway for Hypoxia Regulation in Glioblastoma
Nicolas Skuli et al.
CANCER RESEARCH (2009)
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
Tom Mikkelsen et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
Stuart A. Grossman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Will integrin inhibitors have proangiogenic effects in the clinic?
Michael Weller et al.
NATURE MEDICINE (2009)
Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors
Andrew R. Reynolds et al.
NATURE MEDICINE (2009)
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro
Gabriele D. Maurer et al.
NEURO-ONCOLOGY (2009)
Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography
Oliver Schnell et al.
NEURO-ONCOLOGY (2009)
Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature
Oliver Schnell et al.
BRAIN PATHOLOGY (2008)
The mammary progenitor marker CD61/β3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis
Francois Vaillant et al.
CANCER RESEARCH (2008)
Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
Alejandro D. Ricart et al.
CLINICAL CANCER RESEARCH (2008)
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric brain tumor consortium study PBTC-012
Tobey J. MacDonald et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Integrins in angiogenesis and lymphangiogenesis
Christie J. Avraamides et al.
NATURE REVIEWS CANCER (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors
S. Hariharan et al.
ANNALS OF ONCOLOGY (2007)
A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
L. B. Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro
Sonja Loges et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
L. Burt Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I evaluation of a fully human anti-αv integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors
Saifee A. Mullamitha et al.
CLINICAL CANCER RESEARCH (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation
Marie-Liesse Asselin-Labat et al.
NATURE CELL BIOLOGY (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
Helmut Friess et al.
BMC CANCER (2006)
Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice
Shinya Yamada et al.
NEUROSURGERY (2006)
Integrin αVβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models
Jeffrey M. Albert et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells
V. Samanna et al.
EXPERIMENTAL CELL RESEARCH (2006)
Recent advances in the treatment of malignant astrocytoma
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design
Kathleen W. Beekman et al.
CLINICAL GENITOURINARY CANCER (2006)
A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature
H Jin et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Phase I trial of a monoclonal antibody specific for αvβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion
DG McNeel et al.
CLINICAL CANCER RESEARCH (2005)
Integrin α4β1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation
B Garmy-Susini et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Src kinase activity is required for integrin αVβ3-mediated activation of nuclear factor-κB
DL Courter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
MGMT: Its role in cancer aetiology and cancer therapeutics
SL Gerson
NATURE REVIEWS CANCER (2004)
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma
A Salmaggi et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
FALM Eskens et al.
EUROPEAN JOURNAL OF CANCER (2003)
Spatial expression of VEGF-A in human glioma
M Johansson et al.
JOURNAL OF NEURO-ONCOLOGY (2002)
αν-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin
T Taga et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand
JP Xiong et al.
SCIENCE (2002)
Nanomolar small molecule inhibitors for αvβ6, αvβ5, and αvβ3 integrins
SL Goodman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas
IH Chaudhry et al.
HISTOPATHOLOGY (2001)
Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells
F Aoudjit et al.
ONCOGENE (2001)
αvβ3 and αvβ5 integrin expression in glioma periphery
L Bello et al.
NEUROSURGERY (2001)
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha v integrin antagonist
TJ MacDonald et al.
NEUROSURGERY (2001)
分享论文
